Involvement of various hematopoietic-cell lineages by the JAK2 V617F mutation in polycythemia vera

Takefumi Ishii, Edward Bruno, Ronald Hoffman, Mingjiang Xu

Producción científica: Articlerevisión exhaustiva

125 Citas (Scopus)


The JAK2V617FT mutation has been shown to occur in the overwhelming majority of patients with polycythemia vera (PV). To study the role of the mutation in the excessive production of differentiated hematopoietic cells in PV, CD19+, CD3+, CD34+, CD33 +, and glycophorin A+ cells and granulocytes were isolated from the peripheral blood (PB) of 8 patients with PV and 3 healthy donors mobilized with G-CSF, and the percentage of JAK2V617F mutant allele was determined by quantitative real-time polymerase chain reaction (PCR). The JAK2V617F mutation was present in cells belonging to each of the myeloid lineages and was also present in B and T lymphocytes in a subpopulation of patients with PV. The proportion of hematopoietic cells expressing the JAK2V617F mutation decreased after differentiation of CD34 + cells in vitro in the presence of optimal concentrations of SCF, IL-3, IL-6, and Epo. These data suggest that the JAK2V617F mutation may not provide a proliferative and/or survival advantage for the abnormal PV clone. Although the JAK2V617F mutation plays an important role in the biologic origins of PV, it is likely not the sole event leading to PV.

Idioma originalEnglish (US)
Páginas (desde-hasta)3128-3134
Número de páginas7
EstadoPublished - nov 1 2006
Publicado de forma externa

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology


Profundice en los temas de investigación de 'Involvement of various hematopoietic-cell lineages by the JAK2 V617F mutation in polycythemia vera'. En conjunto forman una huella única.

Citar esto